Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HS-10376
- Development stage
- Phase 2
- Lead developer
- Hansoh Pharmaceutical Group
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
HS-10376 is an orally bioavailable, highly selective small molecule inhibitor that targets both the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2), specifically focusing on tumors with exon 20 insertion mutations in these genes. It is being developed as a targeted therapy for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR and/or HER2 exon 20 insertion mutations. The drug is currently undergoing phase 1/2 clinical trials to evaluate its safety, tolerability, pharmacokinetics, and efficacy in this patient population[1][2][3][5][6].
- Brand names
- HS-10376HS10376HS 10376
- Other names
- EGFR/HER2 mutant-selective inhibitor HS-10376
02
Targets
EGFR T790M (Epidermal growth factor receptor T790M mutant)ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on HS-10376.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HS-10376.